MT2022-57: A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of theSafety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult SubjectsWith Relapsed or Refractory T or B Cell Malignancies

Project: Research project

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry